Cellectar Biosciences, which develops agents to detect, treat and monitor cancers, announced today it has initiated patient dosing in a proof-of-concept trial of I-131-CLR1404 in those with multiple melanoma.
“I-131-CLR1404 has been generally well tolerated in patients and we believe that its selectivity and potency provide a solid rationale for its use in multiple myeloma,” President and CEO of Cellectar Biosciences Dr. Simon Pedder said in a statement. “Based on results from our Phase I trials and the radiosensitivity of multiple myeloma, we believe 12.5 mCi/m2 is a meaningful starting dose of I-131-CLR1404 and evidence of clinical activity will be assessable relatively early in the dose escalation process.”
According to the release, multiple melanoma is a form of blood cancer that primarily affects older adults and arises from plasma cells in the bone marrow. It is the second most common blood cancer in the United States.
